CORT - コ―セプト・セラピュ―ティクス （Corcept Therapeutics Incorporated） コ―セプト・セラピュ―ティクスCORTのチャート
CORTの企業情報
| symbol | CORT |
|---|---|
| 会社名 | Corcept Therapeutics Inc （コ―セプト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 コーセプト・セラピューティクス（Corcept Therapeutics Incorporated）は重篤な代謝と精神・腫瘍疾患の治療薬の発見・開発・商業化に従事する製薬会社である。同社はグルココルチコイド受容体（GR）においてアンタゴニストとして作用することによりコルチゾールの効果を調節する化合物であるミフェプリストンを開発する。同社は選択的コルチゾールモジュレーターであるCORT125134の2つの臨床試験を実施する。同社はクッシング症候群患者の治療法として、CORT125134を検討する。第2の試験では、固形腫瘍がん患者を治療するためのCORT125134とナブパクリタキセルの組み合わせが検討される。 コ―セプト・セラピュ―ティクスは米国の製薬会社。代謝異常、精神疾患、がん細胞などの治療薬の開発と商品化に従事。主要製品はクッシング病を患う成人の高血糖症治療薬｢Korlym｣。また、心因性うつ病治療薬として｢Korlym｣の有効成分であるミフェプリストンの開発も進める。 Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders. |
| 本社所在地 | 149 Commonwealth Drive Menlo Park CA 94025 USA |
| 代表者氏名 | James N. Wilson ジェームズ・N・ウィルソン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-327-3270 |
| 設立年月日 | 35916 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1982年 |
| 従業員数 | 136人 |
| url | www.corcept.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cort |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 77.13800 |
| 終値（lastsale） | 13.295 |
| 時価総額（marketcap） | 1542901262.39 |
| 時価総額 | 時価総額（百万ドル） 1591.063 |
| 売上高 | 売上高（百万ドル） 216.01400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1431.118 |
| 当期純利益 | 当期純利益（百万ドル） 180.97500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Corcept Therapeutics Incorporated revenues increased 90% to $120M. Net income increased from $17M to $35.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.31. |
CORTのテクニカル分析
CORTのニュース
SHAREHOLDER ALERT: Barr Law Group Investigating CORT, SEMMX, MSEIX, and MIMFX; Shareholders are Encouraged to Contact the Firm 2021/06/16 09:00:00 Intrado Digital Media
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the actions of the officers and board of directors of Corcept Therapeutics, Inc., Semper MBS Total Return Fund Institutional Shares, AMG Veritas Asia Pacific Fund - Class I, and AMG Veritas China Fund Class I. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966.
Dupont Capital Management Corp Decreases Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) 2021/05/12 10:06:42 Transcript Daily
Dupont Capital Management Corp lowered its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 17.0% during the first quarter, Holdings Channel reports. The firm owned 33,296 shares of the biotechnology companys stock after selling 6,829 shares during the quarter. Dupont Capital Management Corps holdings in Corcept Therapeutics were worth $792,000 as of its most []
Pituitary ACTH Hypersecretion Drug Market Innovative Strategy by 2028 | Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB 2021/05/11 11:09:08 Jumbo News
JCMR recently Announced Pituitary ACTH Hypersecretion Drug study with 200+ market data Tables and Figures spread through Pages and easy to understand detailed TOC on Global Pituitary ACTH Hypersecretion Drug Market. Global Pituitary ACTH Hypersecretion Drug Market allows you to get different methods for maximizing your profit. The research study provides estimates for Pituitary ACTH Hypersecretion Drug Forecast till 2028*. []
Corcept Therapeutics (NASDAQ:CORT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS 2021/02/25 00:51:45 Transcript Daily
Corcept Therapeutics (NASDAQ:CORT) announced its quarterly earnings results on Monday. The biotechnology company reported $0.20 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01), Fidelity Earnings reports. Corcept Therapeutics had a net margin of 30.73% and a return on equity of 25.38%. The company had revenue of $85.74 […]
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs 2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript 2021/02/09 00:28:18 AlphaStreet
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 earnings call dated Feb. 08, 2021 Corporate Participants: Charles Robb — Chief Financial Officer Joseph K. Belanoff — Chief Executive Officer, President, and Director Presentation: Operator Ladies […] The post Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript first appeared on AlphaStreet .
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO 2021/01/28 13:03:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Kaleido Biosciences Inc (NASDAQ: KLDO ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Nantkwest Inc (NASDAQ: NK ) Penumbra Inc (NYSE: PEN ) Regulus Therapeutics Inc (NASDAQ: RGLS ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Summit Therapeutics Inc (NASDAQ: SMMT ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Vanda Pharmaceuticals Inc.
Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update 2020/11/03 21:05:00 GlobeNewswire
MENLO PARK, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Corcept Therapeutics (NASDAQ:CORT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS 2021/02/25 00:51:45 Transcript Daily
Corcept Therapeutics (NASDAQ:CORT) announced its quarterly earnings results on Monday. The biotechnology company reported $0.20 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01), Fidelity Earnings reports. Corcept Therapeutics had a net margin of 30.73% and a return on equity of 25.38%. The company had revenue of $85.74 […]
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs 2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript 2021/02/09 00:28:18 AlphaStreet
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 earnings call dated Feb. 08, 2021 Corporate Participants: Charles Robb — Chief Financial Officer Joseph K. Belanoff — Chief Executive Officer, President, and Director Presentation: Operator Ladies […] The post Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript first appeared on AlphaStreet .
The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO 2021/01/28 13:03:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT ) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Aziyo Biologics Inc (NASDAQ: AZYO ) Cassava Sciences Inc (NASDAQ: SAVA ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Frequency Therapeutics Inc (NASDAQ: FREQ ) (reacted to ratings upgrade by JPMorgan to Overweight) Fulgent Genetics Inc (NASDAQ: FLGT ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc. (NASDAQ: ILMN ) ImmuCell Corporation (NASDAQ: ICCC ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Kaleido Biosciences Inc (NASDAQ: KLDO ) LeMaitre Vascular Inc (NASDAQ: LMAT ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Nantkwest Inc (NASDAQ: NK ) Penumbra Inc (NYSE: PEN ) Regulus Therapeutics Inc (NASDAQ: RGLS ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Summit Therapeutics Inc (NASDAQ: SMMT ) Supernus Pharmaceuticals Inc (NASDAQ: SUPN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Vanda Pharmaceuticals Inc.